Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis
Author(s) -
Andrew Lau,
Fabian Kong,
Christopher K. Fairley,
David J. Templeton,
Janaki Amin,
Samuel Phillips,
Matthew Law,
Marcus Y. Chen,
Catriona S. Bradshaw,
Basil Donovan,
Anna McNulty,
Mark Boyd,
Peter Timms,
Eric P. F. Chow,
David G. Regan,
Carole Khaw,
David A. Lewis,
John Kaldor,
Mahesh Ratnayake,
Natalie Carvalho,
Jane S. Hocking
Publication year - 2021
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2031631
Subject(s) - azithromycin , chlamydia trachomatis , doxycycline , chlamydia , asymptomatic , medicine , chlamydia trachomatis infection , randomized controlled trial , gynecology , biology , antibiotics , immunology , microbiology and biotechnology
Rectal chlamydia is a common bacterial sexually transmissible infection among men who have sex with men. Data from randomized, controlled trials are needed to guide treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom